Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin (SGN-35) for Relapsed/Refractory Hodgkin Lymphoma Prior to ASCT
NCT01508312Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2012
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01508312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01508312.